Skip to main content
Clinical Trials/NCT04223739
NCT04223739
Unknown
Phase 4

Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery : a Randomized Multicenter Clinical Trial

University Hospital, Caen1 site in 1 country380 target enrollmentDecember 13, 2019

Overview

Phase
Phase 4
Intervention
Landiolol
Conditions
Atrial Fibrillation
Sponsor
University Hospital, Caen
Enrollment
380
Locations
1
Primary Endpoint
Percentage of patients in sinus rhythm 48 hours after the onset of atrial fibrillation immediate postoperative period after cardiac surgery
Last Updated
6 years ago

Overview

Brief Summary

Postoperative atrial fibrillation is a common complication after cardiac surgery with a rate of 30%. However, management of postoperative atrial fibrillation is controversial. Two strategies are recommended : heart rate control using a betablocker or rhythm control with amiodarone.

Landiolol is a new-generation beta-blocker with a short half-life, which was approved by the Haute Autorité de Santé to be used in perioperative supra-ventricular tachycardias.

Only one study compared landiolol to amiodarone in the perioperative setting, with a better hemodynamic tolerance and a higher rate of conversion to sinus rhythm with landiolol. However this was a single-center and retrospective study.

The aim of our multicenter randomized study is to compare the effectiveness of landiolol in reducing atrial fibrillation to sinus rhythm compared to amiodarone in the postoperative period after cardiac surgery.

Detailed Description

Randomized clinical study comparing landiolol and amiodarone for treatment of atrial fibrillation following cardiac surgery

Registry
clinicaltrials.gov
Start Date
December 13, 2019
End Date
June 1, 2022
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients hospitalized in the cardiac ICU after having undergone cardiac surgery (CABG, aortic valve or ascending aortic root replacement or a combination of both)
  • New onset of atrial fibrillation lasting more than 30 minutes in the postoperative period after cardiac surgery
  • French speaking patients
  • Written consent
  • Patients with social security insurance

Exclusion Criteria

  • Hemodynamic instability requiring electrical cardioversion of atrial fibrillation
  • Bradyarrythmia (\< 90/min)
  • Patients requiring inotropes in the postoperative period
  • Patient with pre-existing atrial fibrillation
  • Patient with anticoagulant therapy before surgery
  • Contraindication to amiodarone or beta-blockers
  • Urgent surgery (\< 24h), ventricular assist device, heart transplant, TAVR, mechanical valve, mitral or tricuspid valve replacement.
  • No written consent
  • Pregnant women,
  • Underaged patients (\<18 years old)

Arms & Interventions

Landiolol

Landiolol infusion starting at 2.5 µg/kg/min and titrating up to 80µg/kg/min with a heart rate goal of under 90 bpm.

Intervention: Landiolol

Amiodarone

Amiodarone bolus of 5-7 mg/kg in 1 hour, followed by an infusion of 1g/day until conversion to sinus rhythm.

Intervention: Amiodarone

Outcomes

Primary Outcomes

Percentage of patients in sinus rhythm 48 hours after the onset of atrial fibrillation immediate postoperative period after cardiac surgery

Time Frame: Day 2 after onset of atrial fibrillation

Percentage of patients in sinus rhythm 48 hours after the onset of atrial fibrillation immediate postoperative period after cardiac surgery

Secondary Outcomes

  • Quality of life evaluated by the EQ 5D 3L questionnaire(2 months postsurgery and 1 year postsurgery)
  • Severe hemorrhagic complications due to anticoagulant therapy, as defined by the Haute Autorité de Santé(2 months postsurgery and 1 year postsurgery)
  • Rate of atrial fibrillation recurrence(2 months postsurgery and 1 year postsurgery)
  • Length of hospital stay(Day 8 after onset of atrial fibrillation and through hospital discharge, an average of 14 days)
  • Rate of thrombo-embolic events(2 months postsugery and 1 year postsurgery)
  • Haemodynamic side effects (hypotension, bradycardia)(Day 8 after onset of atrial fibrillation and through hospital discharge, an average of 14 days)

Study Sites (1)

Loading locations...

Similar Trials